T1	Condition 11 27	hypersensitivity
T2	Condition 31 38	allergy
T3	Drug 53 64	study drugs
T4	Non-representable 67 99	rugs of similar chemical classes
T5	Drug 101 123	ACE inhibitors (ACEIs)
T6	Drug 125 164	angiotensin II receptor blockers (ARBs)
T7	Drug 169 190	neprilysin inhibitors
T8	Condition 222 239	contraindications
T9	Mood 203 208	known
T10	Mood 212 221	suspected
*	OR T10 T9
T11	Scope 203 221	known or suspected
R1	Has_scope Arg1:T8 Arg2:T11	
T12	Drug 247 258	study drugs
*	OR T7 T6 T5 T3
T13	Scope 53 190	study drugs, drugs of similar chemical classes, ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or neprilysin inhibitors
*	OR T2 T1
R2	AND Arg1:T8 Arg2:T12	
T14	Scope 11 38	hypersensitivity or allergy
R3	Has_scope Arg1:T14 Arg2:T13	
*	OR T14 T8
T15	Drug 324 329	ACEIs
T16	Drug 333 337	ARBs
T17	Condition 281 292	intolerance
T18	Observation 270 277	history
T19	Temporal 261 269	Previous
R4	Has_temporal Arg1:T17 Arg2:T18	
R5	Has_temporal Arg1:T17 Arg2:T19	
*	OR T15 T16
T20	Scope 324 337	ACEIs or ARBs
R6	Has_scope Arg1:T17 Arg2:T20	
T21	Condition 357 367	angioedema
T22	Drug 406 411	ACEIs
T23	Drug 416 420	ARBs
T24	Procedure 386 395	treatment
T25	Mood 370 385	Requirement for
R7	Has_mood Arg1:T24 Arg2:T25	
*	OR T22 T23
T26	Scope 406 420	ACEIs and ARBs
R8	Has_scope Arg1:T24 Arg2:T26	
T27	Observation 346 353	history
R9	Has_temporal Arg1:T21 Arg2:T27	
T28	Qualifier 431 436	acute
T29	Qualifier 437 450	decompensated
T30	Condition 451 464	heart failure
R10	Has_qualifier Arg1:T30 Arg2:T29	
R11	Has_qualifier Arg1:T30 Arg2:T28	
T31	Condition 466 478	exacerbation
T32	Condition 482 503	chronic heart failure
R12	AND Arg1:T31 Arg2:T32	
T33	Procedure 554 573	intravenous therapy
T34	Condition 518 523	signs
T35	Condition 528 536	symptoms
T36	Scope 518 536	signs and symptoms
T37	Scope 466 503	exacerbation of chronic heart failure
R13	Has_scope Arg1:T37 Arg2:T36	
R14	AND Arg1:T36 Arg2:T33	
T38	Qualifier 577 588	Symptomatic
T39	Condition 589 600	hypotension
R15	Has_qualifier Arg1:T39 Arg2:T38	
T40	Measurement 603 646	Estimated glomerular filtration rate (eGFR)
T41	Value 647 651	<30%
T42	Measurement 654 669	Serum potassium
T43	Value 670 681	>5.4 mmol/L
R16	Has_value Arg1:T42 Arg2:T43	
T44	Condition 684 707	Acute coronary syndrome
T45	Condition 709 715	stroke
T46	Condition 717 743	transient ischaemic attack
T47	Condition 745 752	cardiac
T48	Condition 754 761	carotid
T49	Procedure 772 800	major cardiovascular surgery
T50	Procedure 802 836	percutaneous coronary intervention
T51	Procedure 841 860	carotid angioplasty
T52	Temporal 861 880	within the 3 months
*	OR T49 T50 T51
T53	Scope 772 860	major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty
R17	Has_temporal Arg1:T53 Arg2:T52	
*	OR T48 T47 T46 T45 T44 T53
T54	Condition 895 917	carotid artery disease
T55	Condition 883 891;903 917	Coronary artery disease
T56	Procedure 936 944;961 973	surgical intervention
T57	Mood 918 924	likely
T58	Procedure 948 973	percutaneous intervention
T59	Temporal 974 993	within the 6 months
*	OR T58 T56
T60	Scope 936 973	surgical or percutaneous intervention
R18	Has_mood Arg1:T60 Arg2:T57	
R19	Has_temporal Arg1:T60 Arg2:T59	
*	OR T55 T54
T61	Scope 883 917	Coronary or carotid artery disease
R20	Has_scope Arg1:T61 Arg2:T60	
T62	Device 1014 1060	cardiac resynchronization therapy (CRT) device
T63	Procedure 996 1008	Implantation
R21	AND Arg1:T63 Arg2:T62	
T64	Temporal 1061 1076	within 3 months
T65	Mood 1080 1086	intent
T66	Procedure 1090 1097	implant
T67	Device 1100 1103	CRT
R22	AND Arg1:T66 Arg2:T67	
R23	Has_mood Arg1:T66 Arg2:T65	
R24	Has_temporal Arg1:T63 Arg2:T64	
*	OR T63 T66
T68	Procedure 1117 1133	heart transplant
T69	Observation 1106 1113	History
T70	Observation 1137 1157	on a transplant list
T71	Device 1166 1205	left ventricular (LV) assistance device
R25	Has_temporal Arg1:T68 Arg2:T69	
*	OR T68 T70 T71
T72	Observation 1208 1215	History
T73	Condition 1219 1243	severe pulmonary disease
R26	Has_temporal Arg1:T73 Arg2:T72	
T74	Condition 1295 1309	cardiomyopathy
T75	Procedure 1274 1286	chemotherapy
T76	Qualifier 1274 1294	chemotherapy-induced
T77	Condition 1259 1269	peripartum
T78	Qualifier 1259 1270;1287 1294	peripartum- induced
*	OR T78 T76
T79	Scope 1259 1294	peripartum- or chemotherapy-induced
R27	Has_scope Arg1:T74 Arg2:T79	
T80	Temporal 1310 1330	within the 12 months
R28	Has_temporal Arg1:T74 Arg2:T80	
T81	Condition 1354 1376	ventricular arrhythmia
T82	Qualifier 1344 1353	untreated
R29	Has_qualifier Arg1:T81 Arg2:T82	
T83	Condition 1382 1399	syncopal episodes
T84	Temporal 1400 1419	within the 3 months
R30	AND Arg1:T81 Arg2:T83	
R31	Has_temporal Arg1:T83 Arg2:T84	
T85	Condition 1434 1445	bradycardia
T86	Condition 1473 1495	atrioventricular block
T87	Qualifier 1460 1472	third-degree
T88	Qualifier 1449 1456;1466 1472	second- degree
T89	Negation 1496 1503	without
T90	Device 1506 1515	pacemaker
R32	Has_negation Arg1:T90 Arg2:T89	
*	OR T88 T87
T91	Scope 1449 1472	second- or third-degree
R33	Has_scope Arg1:T86 Arg2:T91	
R34	AND Arg1:T86 Arg2:T90	
*	OR T85 T86
T92	Qualifier 1530 1558	haemodynamically significant
T93	Condition 1573 1593	aortic valve disease
T94	Condition 1559 1565;1580 1593	mitral valve disease
*	OR T94 T93
T95	Scope 1559 1593	mitral and/or aortic valve disease
R35	Has_qualifier Arg1:T95 Arg2:T92	
T96	Condition 1602 1622	mitral regurgitation
T97	Qualifier 1623 1649	secondary to LV dilatation
T98	Condition 1636 1649	LV dilatation
R36	multi Arg1:T97 Arg2:T98	
R37	multi Arg1:T76 Arg2:T75	
R38	multi Arg1:T78 Arg2:T77	
R39	Has_qualifier Arg1:T96 Arg2:T97	
T99	Negation 1595 1601	except
R40	Has_negation Arg1:T96 Arg2:T99	
R41	AND Arg1:T95 Arg2:T96	
T100	Qualifier 1670 1698	haemodynamically significant
T101	Condition 1699 1718	obstructive lesions
T102	Qualifier 1726 1742	LV outflow tract
R42	Has_qualifier Arg1:T101 Arg2:T102	
T103	Condition 1765 1783	subaortic stenosis
T104	Condition 1754 1760;1775 1783	aortic stenosis
*	OR T104 T103
*	OR T101 T100
T105	Scope 1670 1742	haemodynamically significant obstructive lesions of the LV outflow tract
T106	Scope 1754 1783	aortic and subaortic stenosis
R43	Subsumes Arg1:T105 Arg2:T106	
T107	Condition 1790 1798;1810 1819	surgical condition
T108	Condition 1802 1819	medical condition
T109	Condition 1846 1906	alter the absorption, distribution, metabolism, or excretion
T110	Drug 1910 1921	study drugs
R44	AND Arg1:T109 Arg2:T110	
T111	Condition 1994 2020	inflammatory bowel disease
*	OR T107 T108
T112	Scope 1790 1819	surgical or medical condition
R45	AND Arg1:T112 Arg2:T109	
T113	Scope 1790 1921	surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs
T114	Temporal 2021 2041	during the 12 months
T115	Qualifier 1987 1993	active
R46	Has_qualifier Arg1:T111 Arg2:T115	
R47	Has_temporal Arg1:T111 Arg2:T114	
T116	Qualifier 2043 2049	Active
T117	Condition 2050 2058;2070 2076	duodenal ulcers
T118	Condition 2062 2076	gastric ulcers
*	OR T118 T117
T119	Scope 2050 2076	duodenal or gastric ulcers
R48	Has_qualifier Arg1:T119 Arg2:T116	
T120	Temporal 2077 2096	during the 3 months
R49	Has_temporal Arg1:T119 Arg2:T120	
T121	Condition 2110 2125	hepatic disease
T122	Measurement 2169 2195	aspartate aminotransferase
T123	Measurement 2199 2223	alanine aminotransferase
*	OR T123 T122
T124	Value 2231 2265	exceeding 2x upper limit of normal
T125	Scope 2169 2223	aspartate aminotransferase or alanine aminotransferase
R50	Has_value Arg1:T125 Arg2:T124	
T126	Condition 2278 2300	hepatic encephalopathy
T127	Observation 2267 2274	history
R51	Has_temporal Arg1:T126 Arg2:T127	
T128	Condition 2313 2332	oesophageal varices
T129	Observation 2302 2309	history
R52	Has_temporal Arg1:T128 Arg2:T129	
T130	Observation 2337 2344	history
T131	Condition 2348 2365	porto-caval shunt
R53	Has_temporal Arg1:T131 Arg2:T130	
*	OR T131 T128 T126 T125
T132	Procedure 2375 2384	treatment
T133	Temporal 2367 2374	Current
T134	Drug 2390 2404;2419 2425	cholestyramine resins
T135	Drug 2408 2425	colestipol resins
*	OR T134 T135
R54	Has_temporal Arg1:T132 Arg2:T133	
T136	Scope 2390 2425	cholestyramine or colestipol resins
R55	Has_scope Arg1:T132 Arg2:T136	
T137	Mood 2098 2106	Evidence
R56	Has_mood Arg1:T121 Arg2:T137	
T138	Scope 2098 2125	Evidence of hepatic disease
T139	Scope 2169 2425	aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins
R57	Subsumes Arg1:T138 Arg2:T139	
*	OR T111 T119 T138
T140	Scope 1987 2425	active inflammatory bowel disease during the 12 months. Active duodenal or gastric ulcers during the 3 months. Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins
R58	Subsumes Arg1:T113 Arg2:T140	
T141	Observation 2465 2480	life expectancy
T142	Value 2484 2492	<5 years
R59	Has_value Arg1:T141 Arg2:T142	
T143	Condition 2450 2457	disease
T144	Qualifier 2440 2449	any other
R60	Has_qualifier Arg1:T143 Arg2:T144	
R61	Has_context Arg1:T143 Arg2:T141	
